Drug intelligence / Profile preview

Dalpiciclib + Fulvestrant + Gossypol Acetate

Development stage: Phase 2
Lead developer: Hengrui Therapeutics
Administration: Oral, Intramuscular

Overview

This entry is for the combination of dalpiciclib (a CDK4/6 inhibitor), fulvestrant (an estrogen receptor antagonist), and gossypol acetate (a polyphenolic compound). Based on the provided search results, there is no information available about this specific combination being studied or used together as a single therapeutic regimen. Information about gossypol acetate individually was provided, detailing its mechanism of action, clinical development in various cancers (including breast cancer), and safety profile, but not specifically in combination with dalpiciclib and fulvestrant.

Targets

BCL2L1 (B-cell lymphoma-extra large protein)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)ESR2 (ERβ)BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on Dalpiciclib + Fulvestrant + Gossypol Acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dalpiciclib + Fulvestrant + Gossypol Acetate.